Celltrion Gets Phase IIb Green Light For Universal Influenza Antibody Drug
Executive Summary
Hot on the heels of its biosimilar deal with Teva, Celltrion is also making a progress in development of novel drugs, receiving the green light for Phase IIb trial in South Korea for CT-P27, its in-house universal therapeutic antibody product for influenza.
You may also be interested in...
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.